H.C. Wainwright Starts Lipocine Inc (LPCN) at Buy, PT $25
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- After-Hours Movers 10/25: (OGXI) (AKAM) (VRTX) Higher; (EW) (NUVA) (CMG) (AAPL) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
H.C. Wainwright initiated coverage on Lipocine Inc (NASDAQ: LPCN) with a Buy rating and a price target of $25.
Analyst Corey Davis said, "Our Lipocine investment thesis hinges on the success of three late-stage orally-formulated steroid products to better compete with current products that are either injectable or topical. LPCN 1021 (brand name Tylando) is a twice-daily oral formulation of testosterone for hypogonadal men (low testosterone), that received a Complete Response Letter on June 29, 2016 and should have clarity as to the path forward this month. LPCN 1111 is a once-daily next generation prodrug of testosterone that announced successful Phase 2b on September 26. LPCN 1107 is an oral version of hydroxyprogesterone for pre-term birth that would compete directly with Makena and is ready to enter Phase 3."
Shares of Lipocine Inc closed at $4.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Starts Mylan (MYL) at Buy
- Baxter (BAX) PT, Estimates Raised at Evercore ISI
- Oppenheimer Raises Price Target on T-Mobile (TMUS) to $55 Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesH.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!